• Mon, July 9, 2018
  • Tue, July 10, 2018
  • Fri, July 6, 2018

Robyn Karnauskas Upgraded (BIIB) to Strong Buy and Held Target at $371 on, Jul 6th, 2018

Robyn Karnauskas of Citigroup, Upgraded "Biogen Inc." (BIIB) to Strong Buy and Held Target at $371 on, Jul 6th, 2018.

Robyn has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018


These are the ratings of the 3 analyists that currently disagree with Robyn


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Thursday, May 31st, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $369 on, Wednesday, April 25th, 2018
  • Brian Skorney of "Baird" Upgraded from Hold to Buy on, Wednesday, April 25th, 2018

Like: 👍